ERBB4 and neoplasm: The combined inhibition of specific kinases, e.g., HER4 and KAT2A caused significant loss of tumor lipogenesis program leading to suppression of tumor-derived androgen (Fig. 6d, g), indicating its potential as a therapeutic strategy to overcome abiraterone-resistant CRPCs.